首页|A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease

A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
AIM:To compare the efficacy of the proton-pump inhibitor,rabeprazole,with that of the H2-receptor antagonist,ranitidine,as on-demand therapy for relieving symptoms associated with non-erosive reflux disease (NERD).METHODS:This is a single center,prospective,randomized,open-label trial of on-demand therapy with rabeprazole (group A) vs ranitidine (group B) for 4 wk.Eighty-three patients who presented to the American University of Beirut Medical Center with persistent gastroesophageal reflux disease (GERD) symptoms and a normal upper gastrointestinal endoscopy were eligible for the study.Patients in group A (n =44) were allowed a maximum rabeprazole dose of 20 mg twice daily,while those in group B (n =39) were allowed a maximum ranitidine dose of 300 mg twice daily.Efficacy was assessed by patient evaluation of global symptom relief,scores of the SF-36 quality of life (QoL)questionnaires,total number of pills used,and number of medication-free days.RESULTS:Among the 83 patients who were enrolled in the study,76 patients (40 in the rabeprazole group and 36 in the ranitidine group) completed the 4-wk trial.Baseline characteristics were comparable between both groups.After 4 wk,there was no significant difference in the subjective global symptom relief between the rabeprazole and the ranitidine groups (71.4％ vs 65.4％,respectively; P =0.9).There were no statistically significant differences between mean cumulative scores of the SF-36 QoL questionnaire for the two study groups (rabeprazole 22.40 ± 27.53 vs ranitidine 17.28 ± 37.06;P =0.582).There was no significant difference in the mean number of pills used (rabeprazole 35.70 ± 29.75vs ranitidine 32.86 ± 26.98; P =0.66).There was also no statistically significant difference in the mean number of medication-free days between both groups.CONCLUSION:Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD.Both medications were associated with improved quality of life.

Proton-pump inhibitorsH2-receptor antagonistsNon-erosive reflux diseaseGastroesophageal reflux diseaseQuality of life

Abdallah A Kobeissy、Jana G Hashash、Faek R Jamali、Assaad M Skoury、Reham Haddad、Sarah El-Samad、Rami Ladki

展开 >

Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Hamra 1103 2090, Beirut, Lebanon

Department of Surgery, American University of Beirut Medical Center, Hamra 1103 2090, Beirut, Lebanon

Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, PO Box 36, Byblos, Lebanon

2012

10.3748/wjg.v18.i19.2390

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(19)
  • 2
  • 29